Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Major inclusion criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 * Pathologically confirmed relapsed/refractory DLBCL * Subjects must have ≥1 measurable disease site on CT scan (≥ 1.5 cm in longest dimension). * Adequate hepatic and renal function: * AST or ALT ≤2.5 x ULN * Serum Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥60 mL/min/1.73 * Bilirubin ≤1.5 x ULN * Adequate hematologic function: * ANC \>1,000 cells/mm3 * Platelets ≥75,000 cells/mm3 * Hemoglobin ≥8.0 g/dL * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be ≤1.5 x the upper limit of the normal range (ULN) * Must be registered into the Revlimid REMS™program and be willing to comply with the requirements of Revlimid REMS™. Major Exclusion Criteria: * Known central nervous system lymphoma * Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks * Radio- or toxin-immunoconjugates within 10 weeks * Prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug